United States - English - NLM (National Library of Medicine)

genentech, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naprosyn, ec-naprosyn, anaprox, anaprox ds or naprosyn suspension and other treatment options before deciding to use naprosyn, ec-naprosyn, anaprox, anaprox ds or naprosyn suspension. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen as naprosyn, ec-naprosyn, anaprox, anaprox ds or naprosyn suspension is indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naprosyn suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient's weight. naproxen as naprosyn, anaprox, anaprox ds and naprosyn suspension is also indicated: - for relief of the signs and symptoms of tendonitis - for r

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - naproxen 1000mg - modified release tablet - 1000 mg - active: naproxen 1000mg excipient: hypromellose magnesium stearate purified water sunset yellow fcf - naprosyn sr is indicated for its anti-inflammatory and analgesic action in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and other musculoskeletal disorders,

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - naproxen 750mg - modified release tablet - 750 mg - active: naproxen 750mg excipient: hypromellose magnesium stearate purified water sunset yellow fcf - naprosyn sr is indicated for its anti-inflammatory and analgesic action in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and other musculoskeletal disorders,

Canada - English - Health Canada

hoffmann-la roche limited - naproxen - tablet (enteric-coated) - 250mg - naproxen 250mg - other nonsteroidal antiimflammatory agents

United States - English - NLM (National Library of Medicine)

canton laboratories - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - naprosyn tablets, ec-naprosyn, and anaprox ds are indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis naprosyn tablets and anaprox ds are also indicated for: the relief of signs and symptoms of: - tendonitis - bursitis - acute gout the management of: - pain - primary dysmenorrhea naprosyn tablets, ec-naprosyn, and anaprox ds are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see warnings and precautions (5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1) ] risk summary use

United States - English - NLM (National Library of Medicine)

athena bioscience, llc - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naprosyn (naproxen) suspension is indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis - tendonitis - bursitis - acute gout the management of: - pain - primary dysmenorrhea naprosyn suspension is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see warnings and precautions (5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1 cardiovascular thrombotic events) ] risk summary use of nsaids, including naprosyn suspension, can cause premature closure of the fetal ductus arteriosus a

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 250 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; iron oxide yellow; povidone; magnesium stearate - for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 500 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium stearate; iron oxide yellow; povidone - for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 750 mg - tablet, modified release - excipient ingredients: sunset yellow fcf; hypromellose; purified water; magnesium stearate - rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and the relief of chronic pain states in which there is an inflammatory component.

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; purified water; sunset yellow fcf; magnesium stearate - rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and the relief of chronic pain states in which there is an inflammatory component.